Amplicon deep sequencing improves Plasmodium falciparum genotyping in clinical trials of antimalarial drugs.

ABSTRACT: Clinical trials monitoring malaria drug resistance require genotyping of recurrent Plasmodium falciparum parasites to distinguish between treatment failure and new infection occurring during the trial follow up period. Because trial participants usually harbour multi-clonal P. falciparum infections, deep amplicon sequencing (AmpSeq) was employed to improve sensitivity and reliability of minority clone detection. Paired samples from 32 drug trial participants were Illumina deep-sequenced for five molecular markers. Reads were analysed by custom-made software HaplotypR and trial outcomes compared to results from the previous standard genotyping method based on length-polymorphic markers. Diversity of AmpSeq markers in pre-treatment samples was comparable or higher than length-polymorphic mar

SUBMITTER: Gruenberg M 

PROVIDER: S-EPMC6883076 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature